First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Identifieur interne : 001E85 ( Main/Exploration ); précédent : 001E84; suivant : 001E86First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Auteurs : RBID : pubmed:19060176English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal (pharmacokinetics), Antibodies, Monoclonal (therapeutic use), Central Nervous System Neoplasms (immunology), Central Nervous System Neoplasms (pathology), Central Nervous System Neoplasms (radiotherapy), Female, Humans, Lymphoma, B-Cell (immunology), Lymphoma, B-Cell (pathology), Lymphoma, B-Cell (radiotherapy), Lymphoma, Large B-Cell, Diffuse (immunology), Lymphoma, Large B-Cell, Diffuse (pathology), Lymphoma, Large B-Cell, Diffuse (radiotherapy), Male, Middle Aged, Neoplasm Recurrence, Local (immunology), Neoplasm Recurrence, Local (pathology), Neoplasm Recurrence, Local (radiotherapy), Prognosis, Prospective Studies, Radioimmunotherapy, Remission Induction, Survival Rate, Tissue Distribution, Yttrium Radioisotopes (therapeutic use).
- MESH :
- chemical , pharmacokinetics : Antibodies, Monoclonal.
- chemical , therapeutic use : Antibodies, Monoclonal, Yttrium Radioisotopes.
- immunology : Central Nervous System Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local.
- pathology : Central Nervous System Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local.
- radiotherapy : Central Nervous System Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local.
- Adult, Aged, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Radioimmunotherapy, Remission Induction, Survival Rate, Tissue Distribution.
Abstract
Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage. The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 ((90)Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated with the (90)Y-labeled anti-CD20 antibody ibritumomab tiuxetan. Nine patients actually received the planned radioimmunotherapy. In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain. All patients were evaluated for toxicity and response at least 4 weeks after therapy. Four patients responded: one patient had a complete response lasting 30+ months, and three patients had short-lived responses of
DOI: 10.1215/15228517-2008-108
PubMed: 19060176
DOI: 10.1215/15228517-2008-108
PubMed: 19060176
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.</title><author><name sortKey="Maza, Sofiane" uniqKey="Maza S">Sofiane Maza</name><affiliation wicri:level="3"><nlm:affiliation>Department of Hematology, Oncology, and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30/31, 12200 Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Hematology, Oncology, and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30/31, 12200 Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Kiewe, Philipp" uniqKey="Kiewe P">Philipp Kiewe</name></author><author><name sortKey="Munz, Dieter L" uniqKey="Munz D">Dieter L Munz</name></author><author><name sortKey="Korfel, Agnieszka" uniqKey="Korfel A">Agnieszka Korfel</name></author><author><name sortKey="Hamm, Bernd" uniqKey="Hamm B">Bernd Hamm</name></author><author><name sortKey="Jahnke, Kristoph" uniqKey="Jahnke K">Kristoph Jahnke</name></author><author><name sortKey="Thiel, Eckhard" uniqKey="Thiel E">Eckhard Thiel</name></author></titleStmt><publicationStmt><date when="2009">2009</date><idno type="doi">10.1215/15228517-2008-108</idno><idno type="RBID">pubmed:19060176</idno><idno type="pmid">19060176</idno><idno type="wicri:Area/Main/Corpus">002111</idno><idno type="wicri:Area/Main/Curation">002111</idno><idno type="wicri:Area/Main/Exploration">001E85</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Central Nervous System Neoplasms (immunology)</term><term>Central Nervous System Neoplasms (pathology)</term><term>Central Nervous System Neoplasms (radiotherapy)</term><term>Female</term><term>Humans</term><term>Lymphoma, B-Cell (immunology)</term><term>Lymphoma, B-Cell (pathology)</term><term>Lymphoma, B-Cell (radiotherapy)</term><term>Lymphoma, Large B-Cell, Diffuse (immunology)</term><term>Lymphoma, Large B-Cell, Diffuse (pathology)</term><term>Lymphoma, Large B-Cell, Diffuse (radiotherapy)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (immunology)</term><term>Neoplasm Recurrence, Local (pathology)</term><term>Neoplasm Recurrence, Local (radiotherapy)</term><term>Prognosis</term><term>Prospective Studies</term><term>Radioimmunotherapy</term><term>Remission Induction</term><term>Survival Rate</term><term>Tissue Distribution</term><term>Yttrium Radioisotopes (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Yttrium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Central Nervous System Neoplasms</term><term>Lymphoma, B-Cell</term><term>Lymphoma, Large B-Cell, Diffuse</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Central Nervous System Neoplasms</term><term>Lymphoma, B-Cell</term><term>Lymphoma, Large B-Cell, Diffuse</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Central Nervous System Neoplasms</term><term>Lymphoma, B-Cell</term><term>Lymphoma, Large B-Cell, Diffuse</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Prospective Studies</term><term>Radioimmunotherapy</term><term>Remission Induction</term><term>Survival Rate</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage. The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 ((90)Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated with the (90)Y-labeled anti-CD20 antibody ibritumomab tiuxetan. Nine patients actually received the planned radioimmunotherapy. In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain. All patients were evaluated for toxicity and response at least 4 weeks after therapy. Four patients responded: one patient had a complete response lasting 30+ months, and three patients had short-lived responses of </div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19060176</PMID><DateCreated><Year>2009</Year><Month>08</Month><Day>07</Day></DateCreated><DateCompleted><Year>2009</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1522-8517</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuro-oncology</Title><ISOAbbreviation>Neuro-oncology</ISOAbbreviation></Journal><ArticleTitle>First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.</ArticleTitle><Pagination><MedlinePgn>423-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1215/15228517-2008-108</ELocationID><Abstract><AbstractText>Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage. The aim of this phase II trial was to evaluate the therapeutic efficacy, toxicity, and biodistribution of yttrium-90 ((90)Y) ibritumomab tiuxetan in PCNSL. Ten patients with relapsed PCNSL were included in a phase II trial and treated with the (90)Y-labeled anti-CD20 antibody ibritumomab tiuxetan. Nine patients actually received the planned radioimmunotherapy. In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain. All patients were evaluated for toxicity and response at least 4 weeks after therapy. Four patients responded: one patient had a complete response lasting 30+ months, and three patients had short-lived responses of </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maza</LastName><ForeName>Sofiane</ForeName><Initials>S</Initials><Affiliation>Department of Hematology, Oncology, and Transfusion Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30/31, 12200 Berlin, Germany.</Affiliation></Author><Author ValidYN="Y"><LastName>Kiewe</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Munz</LastName><ForeName>Dieter L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Korfel</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hamm</LastName><ForeName>Bernd</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Jahnke</LastName><ForeName>Kristoph</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Thiel</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial, Phase II</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuro Oncol</MedlineTA><NlmUniqueID>100887420</NlmUniqueID><ISSNLinking>1522-8517</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Yttrium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>ibritumomab tiuxetan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Neurooncol. 1999 Jul;43(3):249-57</RefSource><PMID Version="1">10563431</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2002 May 15;20(10):2453-63</RefSource><PMID Version="1">12011122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2003 Jan 15;101(2):466-8</RefSource><PMID Version="1">12393404</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 1991;27(11):1356-61</RefSource><PMID Version="1">1835848</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1998 Sep 15;92(6):1927-32</RefSource><PMID Version="1">9731049</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2005 Apr;74(4):348-52</RefSource><PMID Version="1">15777348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2007 Dec 1;110(11):2528-34</RefSource><PMID Version="1">17932895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2005 Oct;16(10):1710-1</RefSource><PMID Version="1">15972281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurooncol. 2006 Mar;77(1):53-8</RefSource><PMID Version="1">16283435</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8</RefSource><PMID Version="1">17229341</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurooncol. 2007 Jul;83(3):291-3</RefSource><PMID Version="1">17245621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2007 Sep;48(9):1712-20</RefSource><PMID Version="1">17786706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 1;23(22):5034-43</RefSource><PMID Version="1">15955902</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Central Nervous System Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymphoma, B-Cell</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymphoma, Large B-Cell, Diffuse</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Radioimmunotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Yttrium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC2743222</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2008</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">15228517-2008-108</ArticleId><ArticleId IdType="doi">10.1215/15228517-2008-108</ArticleId><ArticleId IdType="pubmed">19060176</ArticleId><ArticleId IdType="pmc">PMC2743222</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19060176
|texte= First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19060176" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |